Skip to the beginning of the images gallery

Venture Capital in Biotechnology

Matherne, G. (Paul) ; Herpfer, Christoph ; Dow, Ethan

Reference: DARDEN-OM-1796-E
Number of pages: 8
Publication Date: Dec 5, 2023
Source: Darden University of Virginia (USA)
Type of Document: Technical Note
Industry Setting: Healthcare

Grouped product items
Format	Language	Reference	Use	Qty	Price	Preview
pdf	English	DARDEN-OM-1796-E			As low as €8.20	Preview

You already have a subscription

To order please contact the person in charge of academic purchases in your university.

You'll be able to order once your profile has been validated.

Description

Pharmaceutical companies have historically relied on their ability to research, develop, manufacture, and sell drug products. Developing a successful drug is a complex and lengthy process, with no guarantee of success, and the total cost of approving a new drug is estimated at $2.5 billion, and rising. This technical note offers an overview of changes in the biotechnology industry related to drug development, focusing on M&A, the milestone model, and venture capital.

Keywords

Big Pharma biologic biotech Biotechnology clinical trial drug development entrepreneur FDA Food and Drug Administration Hatch-Waxman Incubator M&A medicine milestone model pharma pharmaceutical philanthrocapitalism R&D start-up VC Venture capital